NCT02811185View on ClinicalTrials.gov

Registry Type Study to Monitor for Adverse Drug Reactions to Fedoruk Manufactured [F-18]-Fludeoxyglucose

PHASE4CompletedINTERVENTIONAL
Enrollment

1,012

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

January 31, 2017

Study Completion Date

January 30, 2017

Conditions
Positron-Emission Tomography and Cone-Beam Computed Tomography
Interventions
DRUG

[F-18]-Fludeoxyglucose

Radiopharmaceutical imaging agent

All Listed Sponsors
collaborator

Sylvia Fedoruk Canadian Centre for Nuclear Innovation

OTHER

collaborator

Saskatoon Health Region

OTHER

lead

University of Saskatchewan

OTHER

NCT02811185 - Registry Type Study to Monitor for Adverse Drug Reactions to Fedoruk Manufactured [F-18]-Fludeoxyglucose | Biotech Hunter | Biotech Hunter